Soleno Therapeutics, Inc. (SLNO) Stock Analysis

Soleno Therapeutics, Inc. (SLNO) Healthcare & Pipeline Overview

Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in rare disease therapeutics, primarily focused on Prader-Willi Syndrome. Their lead candidate, Diazoxide Choline Controlled-Release, is in Phase III trials, positioning them as a potential key player in the rare disease treatment landscape with a significant unmet medical need.

What Is the Investment Thesis for SLNO?

Soleno Therapeutics presents a focused investment opportunity within the rare disease biotechnology sector. The company's valuation is significantly influenced by the progress and potential success of Diazoxide Choline Controlled-Release (DCCR) in treating Prader-Willi Syndrome (PWS). Positive Phase III trial results and subsequent FDA approval could serve as major catalysts, driving substantial revenue growth. The company's current market capitalization of $2.76B reflects investor expectations regarding DCCR's market potential, given the high unmet need in PWS treatment. Profit margin is 33.7% and gross margin is 65.9%. Key risks include clinical trial setbacks, regulatory hurdles, and competition from alternative therapies. Successful commercialization of DCCR would solidify Soleno's position and justify its current valuation.

Based on FMP financials and quantitative analysis

SLNO Key Highlights

Market capitalization of $2.76B, reflecting investor confidence in the potential of Diazoxide Choline Controlled-Release (DCCR).

• Profit margin of 33.7%, indicating strong profitability potential upon successful commercialization of DCCR.
• Gross margin of 65.9%, showcasing efficient cost management in the development of their lead candidate.
• Ongoing Phase III clinical development program for Diazoxide Choline Controlled-Release (DCCR) targeting Prader-Willi Syndrome.
• Beta of -2.81, suggesting a low correlation with overall market movements, potentially offering portfolio diversification benefits.

Who Are SLNO's Competitors?

SLNO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are SLNO's Key Strengths?

Proprietary Diazoxide Choline Controlled-Release (DCCR) formulation.

• Focus on a rare disease with high unmet medical need.
• Ongoing Phase III clinical trials with promising results.
• Strong intellectual property protection.

What Are SLNO's Weaknesses?

Reliance on a single lead product candidate.

• High clinical trial and regulatory risks.
• Limited commercialization experience.
• Potential competition from alternative therapies.

What Could Drive SLNO Stock Higher?

SLNO catalyst: Announcement of topline results from the Phase III clinical trial of Diazoxide Choline Controlled-Release (DCCR) in Prader-Willi Syndrome (PWS) expected in Q4 2026.

• Potential FDA submission and approval of Diazoxide Choline Controlled-Release (DCCR) for the treatment of Prader-Willi Syndrome (PWS) anticipated in 2027.
• Progress in securing strategic partnerships for commercialization of Diazoxide Choline Controlled-Release (DCCR).
• Expansion of intellectual property protection for Diazoxide Choline Controlled-Release (DCCR) and related technologies.

What Are the Key Risks for SLNO?

Rich valuation — a P/E of 28.8 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.

• Failure to achieve positive results in the Phase III clinical trial of Diazoxide Choline Controlled-Release (DCCR).
• Regulatory setbacks or rejection of Diazoxide Choline Controlled-Release (DCCR) by the FDA.
• Competition from alternative therapies for Prader-Willi Syndrome (PWS).
• Dependence on successful commercialization of a single lead product candidate.
• Risks associated with manufacturing and supply chain management for Diazoxide Choline Controlled-Release (DCCR).

What Are the Growth Opportunities for SLNO?

• Expansion into Additional Indications: Soleno Therapeutics could explore the potential of Diazoxide Choline Controlled-Release (DCCR) in treating other rare diseases characterized by hyperphagia or metabolic dysfunction. This strategic expansion could significantly broaden the addressable market beyond Prader-Willi Syndrome (PWS). The market size for related metabolic disorders is estimated to reach $15 billion by 2030, presenting a substantial growth opportunity. Timeline: 3-5 years.
• Geographic Expansion: Currently focused on the US market, Soleno Therapeutics has the opportunity to expand into European and Asian markets, where Prader-Willi Syndrome (PWS) patients also represent a significant unmet need. Securing regulatory approvals in these regions could substantially increase revenue streams. The European market for rare disease treatments is projected to reach $60 billion by 2028. Timeline: 2-4 years.
• Strategic Partnerships and Collaborations: Soleno Therapeutics could pursue strategic partnerships with larger pharmaceutical companies to accelerate the commercialization of Diazoxide Choline Controlled-Release (DCCR) and expand its market reach. Collaborations could also facilitate the development of combination therapies or novel formulations. Such partnerships could unlock additional funding and expertise. Timeline: Ongoing.
• Lifecycle Management of DCCR: Soleno Therapeutics can focus on lifecycle management strategies for Diazoxide Choline Controlled-Release (DCCR), including the development of improved formulations, delivery methods, or combination therapies. These efforts can extend the product's market exclusivity and maintain its competitive advantage. This could involve exploring extended-release formulations or pediatric-specific dosages. Timeline: Ongoing.
• Acquisition of Complementary Assets: Soleno Therapeutics could strategically acquire or in-license complementary assets, such as other rare disease therapeutics or diagnostic tools, to diversify its product portfolio and expand its presence in the rare disease market. This could involve acquiring companies with promising early-stage assets or established market access. Timeline: 2-5 years.

What Threats Does SLNO Face?

• Clinical trial failures or delays.
• Regulatory setbacks or rejection of DCCR.
• Competition from new or existing therapies.
• Changes in reimbursement policies or pricing pressures.

What Are SLNO's Competitive Advantages?

• Proprietary drug formulation of Diazoxide Choline Controlled-Release (DCCR).
• Orphan drug designation for Prader-Willi Syndrome (PWS), providing market exclusivity.
• Strong intellectual property protection through patents.
• Clinical data supporting the safety and efficacy of DCCR.
• Established relationships with key opinion leaders in the PWS field.

What Does SLNO Do?

Soleno Therapeutics, Inc., established in 1999 and based in Redwood City, California, is dedicated to the development and commercialization of innovative therapies for rare diseases. Originally incorporated as Capnia, Inc., the company rebranded to Soleno Therapeutics, Inc. in May 2017 to reflect its evolved strategic focus. The company's primary focus is on addressing unmet medical needs in rare disease populations, particularly Prader-Willi Syndrome (PWS). Their lead product candidate, Diazoxide Choline Controlled-Release (DCCR), is a proprietary, once-daily oral tablet designed to treat PWS. DCCR is currently undergoing Phase III clinical trials, representing a critical stage in its development and potential regulatory approval. Prader-Willi Syndrome is a complex genetic disorder characterized by hyperphagia, a persistent feeling of insatiable hunger, which can lead to severe obesity and other health complications. Soleno Therapeutics aims to provide a targeted therapeutic solution to manage hyperphagia and improve the overall quality of life for individuals with PWS. The company's commitment to rare diseases underscores its mission to innovate and deliver meaningful treatments to underserved patient populations.

What Products and Services Does SLNO Offer?

• Develops novel therapeutics for rare diseases.
• Focuses on treating Prader-Willi Syndrome (PWS).
• Conducts Phase III clinical trials for Diazoxide Choline Controlled-Release (DCCR).
• Aims to commercialize DCCR as a once-daily oral tablet.
• Addresses hyperphagia and related complications in PWS patients.
• Seeks regulatory approval from the FDA and other agencies.
• Manages clinical development programs and research activities.

How Does SLNO Make Money?

• Develops and patents proprietary drug formulations.
• Conducts clinical trials to demonstrate safety and efficacy.
• Seeks regulatory approval for commercialization.
• May partner with larger pharmaceutical companies for distribution and marketing.
• Generates revenue through sales of approved therapeutics.

What Industry Does SLNO Operate In?

Soleno Therapeutics operates within the biotechnology industry, specifically targeting the rare disease therapeutics market. This sector is characterized by high unmet medical needs, accelerated regulatory pathways, and potential for premium pricing. The market for rare disease treatments is expanding, driven by increased awareness, improved diagnostics, and regulatory incentives such as orphan drug designation. Soleno's focus on Prader-Willi Syndrome positions it within a niche segment of this market. Competitors like Praxis Precision Medicines, Inc. (PRAX) and Xenon Pharmaceuticals Inc. (XENE) also operate in the broader biotechnology space, but Soleno's specific focus on PWS differentiates it.

Who Are SLNO's Key Customers?

• Patients diagnosed with Prader-Willi Syndrome (PWS).
• Caregivers and families of PWS patients.
• Physicians specializing in endocrinology and genetics.
• Hospitals and clinics treating PWS patients.
• Managed care organizations and insurance companies.

Wall Street analysts project Soleno Therapeutics, Inc. revenue of about $462.1M for fiscal 2026, with EPS near $3.81. The estimate reflects 6 contributing analysts.

Soleno Therapeutics, Inc.'s Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 15.37 places it in the safe zone, indicating low near-term bankruptcy risk.

Return on equity for Soleno Therapeutics, Inc. stands at 22.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 15.8%, showing how much profit it generates from its asset base. SLNO trades at a trailing price-to-earnings ratio of 28.75, above the Healthcare sector average of ~23x. Its free cash flow yield is 3.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.62 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 3.5%, the inverse of the P/E and a quick read on earnings relative to price.

Soleno Therapeutics, Inc. (SLNO) Valuation Context

Valued at $2.76B, SLNO is classified as a mid-cap stock.

Company Profile

Soleno Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Redwood City, US. The company is led by CEO Anish Bhatnagar. SLNO has traded publicly since 2014.

SLNO Financials

SLNO Latest News

No recent news available for SLNO.

Latest Soleno Therapeutics, Inc. Analysis

Common Questions About SLNO (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources